RU2440100C2 - Новые фармацевтические композиции, полезные в лечении болезни паркинсона - Google Patents

Новые фармацевтические композиции, полезные в лечении болезни паркинсона Download PDF

Info

Publication number
RU2440100C2
RU2440100C2 RU2007139826/15A RU2007139826A RU2440100C2 RU 2440100 C2 RU2440100 C2 RU 2440100C2 RU 2007139826/15 A RU2007139826/15 A RU 2007139826/15A RU 2007139826 A RU2007139826 A RU 2007139826A RU 2440100 C2 RU2440100 C2 RU 2440100C2
Authority
RU
Russia
Prior art keywords
particles
composition according
composition
carrier
active ingredient
Prior art date
Application number
RU2007139826/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007139826A (ru
Inventor
Андерс ПЕТТЕРССОН (SE)
Андерс Петтерссон
Томас ЛУНДКВИСТ (SE)
Томас ЛУНДКВИСТ
Original Assignee
Орексо Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орексо Аб filed Critical Орексо Аб
Publication of RU2007139826A publication Critical patent/RU2007139826A/ru
Application granted granted Critical
Publication of RU2440100C2 publication Critical patent/RU2440100C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2007139826/15A 2005-03-28 2006-03-28 Новые фармацевтические композиции, полезные в лечении болезни паркинсона RU2440100C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66537605P 2005-03-28 2005-03-28
US60/665,376 2005-03-28

Publications (2)

Publication Number Publication Date
RU2007139826A RU2007139826A (ru) 2009-05-10
RU2440100C2 true RU2440100C2 (ru) 2012-01-20

Family

ID=34956744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007139826/15A RU2440100C2 (ru) 2005-03-28 2006-03-28 Новые фармацевтические композиции, полезные в лечении болезни паркинсона

Country Status (13)

Country Link
US (1) US20080193526A1 (OSRAM)
EP (1) EP1863455A1 (OSRAM)
JP (1) JP2008534563A (OSRAM)
KR (1) KR20070114734A (OSRAM)
CN (1) CN101141949B (OSRAM)
AU (1) AU2006228296B2 (OSRAM)
CA (1) CA2599384A1 (OSRAM)
IL (1) IL185300A0 (OSRAM)
MX (1) MX2007011976A (OSRAM)
NO (1) NO20074199L (OSRAM)
NZ (1) NZ560826A (OSRAM)
RU (1) RU2440100C2 (OSRAM)
WO (1) WO2006103417A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
AU2008343787B2 (en) * 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
KR101850479B1 (ko) 2015-07-22 2018-05-30 (주)듀켐바이오 [18F]플루오로-도파의 중성 pH 안정화 방법
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2076700C1 (ru) * 1991-01-30 1997-04-10 Эгиш Дьедьсердьяр Способ изготовления твердых фармацевтических составов
RU2114619C1 (ru) * 1991-01-23 1998-07-10 Изис Фарма ГмбХ Перорально вводимая лекарственная форма
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414167B1 (OSRAM) * 1970-12-28 1979-06-05
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
CA2512559A1 (en) * 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2114619C1 (ru) * 1991-01-23 1998-07-10 Изис Фарма ГмбХ Перорально вводимая лекарственная форма
RU2076700C1 (ru) * 1991-01-30 1997-04-10 Эгиш Дьедьсердьяр Способ изготовления твердых фармацевтических составов
US6316027B1 (en) * 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONDO W. et al., A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov.Disord. 1999, v. 14, №4, p.664-8, PMID: 10435505. *

Also Published As

Publication number Publication date
RU2007139826A (ru) 2009-05-10
AU2006228296B2 (en) 2011-08-04
NZ560826A (en) 2009-06-26
US20080193526A1 (en) 2008-08-14
MX2007011976A (es) 2007-12-07
KR20070114734A (ko) 2007-12-04
JP2008534563A (ja) 2008-08-28
WO2006103417A1 (en) 2006-10-05
EP1863455A1 (en) 2007-12-12
IL185300A0 (en) 2008-02-09
NO20074199L (no) 2007-11-21
CA2599384A1 (en) 2006-10-05
CN101141949B (zh) 2010-12-08
AU2006228296A1 (en) 2006-10-05
CN101141949A (zh) 2008-03-12

Similar Documents

Publication Publication Date Title
EP2341910B1 (en) Immediate release dosage forms of sodium oxybate
US20060100214A1 (en) Fast dissolving and taste masked oral dosage form comprising sildenafil
US20090232898A1 (en) Pharmaceutical Compositions Useful in the Treatment of Migraine
JPH10182436A (ja) 固形医薬製剤
NO326259B1 (no) Faste oralt-dispergerbare farmasoytiske formuleringer
CN101141949B (zh) 用于治疗帕金森病的药物组合物
CN104427978B (zh) 用于治疗急性疼痛的阿芬太尼组合物
US9265720B2 (en) Pharmaceutical formulations useful in the treatment of insomnia
MXPA05001127A (es) Formulacion de bicifadina.
MXPA04009906A (es) Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda.
WO2005120463A1 (en) Rapidly disintegrating tablets of risperidone
CA2893480C (en) Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
JPS60237018A (ja) 口腔内付着性組成物
TW201729798A (zh) 口腔內保持型崩解性固形製劑、其製造方法、及用於該製造方法之粉體組成物
HK1212229B (en) Pharmaceutical formulation of n- [5- [2-(3,5-dimethoxyphenyl) ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120329